Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
about
Adenovirus vectors for gene therapy, vaccination and cancer gene therapyTransduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapyOncolytic viruses: From bench to bedside with a focus on safety.Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Oncolytic immunotherapy: where are we clinically?Chapter two--Adenovirus strategies for tissue-specific targeting.Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Increasing the efficacy of oncolytic adenovirus vectorsInduction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumorsPreclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumorsAttenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesBiodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemiaSerotype chimeric human adenoviruses for cancer gene therapy.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.Oncolytic adenovirus based on serotype 3.Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.Treatment of chemotherapy-refractory cancer in the advanced therapy access program.Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNISIn vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.
P2860
Q27001601-5E0222DE-DDFB-4404-A3F6-2E5891C819D6Q33700352-14C2EDE9-829F-4FD5-AA6D-C90A03E284D8Q34044071-6A8E28A0-846D-4D21-A222-0264B0F3366BQ34178183-4BB7779D-975E-4396-B503-3E9B69856488Q34405325-6CA4018B-ADA8-40D3-AEC7-E23E37916C98Q34643252-2ACCC59B-1C75-4DCE-8425-B7066B2C2E47Q35224606-FBED4729-AFED-4CF3-AE97-867821777C75Q35238258-8589243D-5504-4D54-B19A-C5051D3BCE13Q35261325-3ECD253D-2DB1-46AA-9BFD-9F04C098359BQ35285768-5F895AE6-068D-4958-81A0-ACB80A5CB5B9Q35506253-0D9602EA-9E1E-4F95-AAC0-B4893DA1F058Q35599319-EAE281EA-D819-4D54-8E51-31D9E1768D22Q35651085-7C994655-6094-431F-92AA-ED11E56997C9Q35653264-913B320A-11B8-44D8-854F-B1EE90295F47Q35717021-2E57BDE6-55B0-4706-A2BE-E3C263E8D76FQ36023115-9B9D1ABA-7128-46F2-BBC1-E1A059C6990FQ36220624-4B9EBB54-A7FF-41E5-9F39-6F941896F43CQ36664201-0119CEFE-804B-4E18-89BE-6895C0A433DAQ36757131-D1CE5BDC-47D0-4BDE-81CD-0C74DE9DC317Q36925337-9A3CD5B2-BA71-4A3F-AA90-5F514C0DADE4Q37132233-9EB4F49D-26BA-4AB4-917D-3D6618082C60Q37945193-104A36B3-2B0C-4349-9CA4-D7BC9747F66DQ38614156-EEACDC0C-04B7-4A3A-B413-58996D432797Q39308911-351F7817-1A46-400A-AE63-7DF6FD03C62FQ39532576-13D55307-81F1-43B6-A6A5-BA1ADD865DA3Q39616158-541479B6-C4FD-4A40-8038-A994E7C53CACQ39868041-127E99ED-2AE6-4968-B948-72CEC294486BQ40087457-F9C44F90-C344-4FFE-ACC1-99010636B82AQ42254679-D6C3B6DA-88FE-481D-B605-02F7900B8892Q42324174-F6C2E5EE-74F9-4771-AC30-FB5925A2A85AQ42709652-5EC3CB37-0E75-4729-832B-A279DBBE7ADBQ45866594-ACD96300-00DB-4146-A541-7F2A53493918Q45869559-94B2199B-CB0A-4E23-B159-2E3CA0006170Q49787495-AE1B765B-AE88-42EE-A806-186587781D36
P2860
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prolonged systemic circulation ...... c and refractory solid tumors.
@ast
Prolonged systemic circulation ...... c and refractory solid tumors.
@en
type
label
Prolonged systemic circulation ...... c and refractory solid tumors.
@ast
Prolonged systemic circulation ...... c and refractory solid tumors.
@en
prefLabel
Prolonged systemic circulation ...... c and refractory solid tumors.
@ast
Prolonged systemic circulation ...... c and refractory solid tumors.
@en
P2093
P356
P1433
P1476
Prolonged systemic circulation ...... c and refractory solid tumors.
@en
P2093
A Helminen
A Hemminki
A Karioja-Kallio
A Ristimäki
E Haavisto
G Bauerschmitz
P2888
P304
P356
10.1038/GT.2010.17
P577
2010-03-18T00:00:00Z
P5875
P6179
1021553080